Seife EdomAyalew Zerubbabel2022-06-062023-11-052022-06-062023-11-052022-02http://etd.aau.edu.et/handle/123456789/31927Background:Colorectal cancer is the third most diagnosed and second leading cause of cancer death globally.Rectal cancer accounts for about one-third of these cases and is treated through multimodal approaches — surgery, chemotherapy, and radiotherapy.Despite global advances, local evidence in Ethiopia is limited, prompting this study Objective:evaluate treatment response, resectability, and surgico-pathologic outcomes in rectal cancer patients treated with neoadjuvant chemoradiotherapy at TASH. Methodology:A retrospective study of 37 patients treated between 2014 and 2021.Data were collected from patient charts after screening 205 cases who received radiotherapy.Basic descriptive analysis was used to interpret res Key FindingsMajority had advanced disease (cT4b) and MRF positive status.Clinical response (tumor downstaging) Resectability rate: 30%.APR surgery was most common (81.8%), with 63.6% achieving R0 resection (complete tumor removal) Keywords:Rectal cancer, neoadjuvant chemoradiotherapy, clinical stage, pathologic stage, TASH, Ethiopia.Would you like me to extract the key results and conclusions section next? That would give a clearer picture of the study’s outcomes and implications for treatment.ZerubbabeAyalewl. PDF.pdf+4 tabsen-USThesis